SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
The Diabetes Educator
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Edelman, S. V.
Right arrow Articles by Caballero, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edelman, S. V.
Right arrow Articles by Caballero, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

FEATURES

Amylin Replacement Therapy in Patients With Type 1 Diabetes

Steven V. Edelman, MD and Leo Caballero, MD

From the University of California, San Diego.

Correspondence to Steven V. Edelman, MD, University of California, San Diego, Veterans Affairs Medical Center, 3550 La Jolla Village Drive 111G, San Diego, CA 92161 (svedelman{at}vapop.ucsd.edu).

Amylin is a pancreatic ß-cell hormone that is cosecreted with insulin and plays an important physiologic role in glucose homeostasis. Pramlintide is an analogue of amylin recently approved by the Food and Drug Administration and represents the first new treatment for people with type 1 diabetes since the discovery of insulin more than 80 years ago. Pramlintide has been shown to reduce the day-to-day fluctuations in glucose values that are commonly seen despite maximized insulin therapy alone. Additional proven clinical benefits include flattening of the postprandial glucose values, reducing the A1C, and concomitant weight loss. This combination of benefits makes pramlintide an important therapeutic tool for improving the metabolic control and quality of life of people with type 1 diabetes.

The Diabetes Educator, Vol. 32, No. Supplement 3, 119S-127S (2006)
DOI: 10.1177/0145721706288236
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement